Status:
COMPLETED
Estimating Lymphocyte Counts from DNA Methylation
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Conditions:
Colorectal Cancers
Immunotherapy
Eligibility:
All Genders
18-80 years
Brief Summary
The goal of this observational study is to assess lymphocyte levels in colorectal cancer patients using DNA methylation levels in tissues or blood. The main questions it aims to answer are: Can DNA m...
Eligibility Criteria
Inclusion
- Diagnosed with colorectal cancer by colonoscopy pathology and deemed eligible for immunotherapy after assessment.
- Neoadjuvant immunotherapy regimen includes PD-1 or anti-PD-L1.
- R0 resection is performed after neoadjuvant immunotherapy.
- Complete immunotherapy efficacy assessment data and follow-up data are available.
- The tissue bank stores the required whole blood and tissue samples for the experiment.
Exclusion
- Concurrent other malignancies.
- Neoadjuvant immunotherapy not conducted according to the standard protocol.
- Severe adverse chemotherapy reactions that lead to the discontinuation of immunotherapy midway.
- Lack of complete neoadjuvant chemotherapy efficacy assessment data or follow-up data.
- The tissue bank does not store the required whole blood or tissue samples for the experiment.
- Patients with concurrent other immune system diseases.
Key Trial Info
Start Date :
January 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2024
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT06586307
Start Date
January 1 2023
End Date
July 1 2024
Last Update
September 19 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Sixth Affiliate Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510655